Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 669

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 5
Chunk 669
---
 monitors budget versus actual results using
consolidated loss from operations. 

Significant expenses
within loss from operations, as well as within net loss, include research and development and general and administrative expenses, which
are each separately presented on the Company’s Consolidated Statements of Operations and Comprehensive Loss. Other segment items
within net loss include other income (expense), net.

The Company’s long-lived
assets consist primarily of acquired in-process research and development intangible assets which are located in the United States.

NOTE
14 – SUBSEQUENT EVENTS

Cordstrom License Agreement 

On February 6, 2025, the Company and GOSH entered into a license agreement
for the exclusive commercial use to clinical trial data associated with the Mission EB study investigating the potential of CORDStrom
to treat RDEB in pediatric patients. The Company owns the intellectual property covering CORDStrom, the investigational medicinal product
used in the Mission EB study. In addition, the Company owns intellectual property and maintains trade secret protections covering the
manufacturing of CORDStrom. With this license to the clinical trial data, the Company intends to prepare applications seeking marketing
authorization of CORDStrom for treatment of pediatric RDEB in each of the FDA, EMA, and MHRA. Terms of the license agreement include an
upfront payment of £250,000 (approximately $0.3 million at February 6, 2025) and a single milestone payment of up to £6,000,000
(approximately $7.5 million at February 6, 2025) due on the first to occur marketing authorization to be granted by the FDA, EMA or MHRA.
In addition to these financial terms, the Company has also agreed to certain patient access obligations, including sponsoring the supply
of CORDStrom to UK patients enrolled in an open label continuation of the Mission EB study.

Sales of Common Stock

During the period from January 1, 2025 through March 27, 2025, the
Company sold 649,860 shares of its common stock through its ATM program for net proceeds of $5.3 million.

F-20

Item 9. Changes in and Disagreements with Accountants
on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our
Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls